Evoke Pharma announces issuance of new U.S. patent for GIMOTI

Evoke Pharma (EVOK) announced the official issuance of a new U.S. patent related to its product GIMOTI. The patent, U.S. Patent No. 12,377,064, covers the use of intranasal metoclopramide in patients with moderate to severe symptoms of gastroparesis, and has now been issued by the United States Patent and Trademark Office. Importantly, the patent term has been extended by the USPTO to November 2038, due to patent term adjustments, extending market exclusivity for GIMOTI two years beyond the previously projected expiration in December 2036. The company plans to list this newly issued patent in the FDA’s Orange Book, further strengthening GIMOTI’s intellectual property position.